Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 5

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 5
---
 RDEB and many other debilitating conditions. CORDStrom for the treatment of children with RDEB has completed a pivotal blinded
randomized cross-over trial. The data will be submitted for a marketing authorization by filing a Biologics License Application (“BLA”)
with the FDA which is anticipated by the end of 2025 or early 2026. Afterwards,
the Company intends to file a Marketing Authorization Application (“MAA”) in the UK and EU in 2026. The FDA granted RPDD to
the Company’s CORDStrom product on December 13, 2024, ahead of the sunset period under Section 529(b)(5) of the Federal Food, Drug,
and Cosmetic Act. As such, CORDStrom remains eligible to receive a Priority Review Voucher (“PRV”) if approved by the FDA
on or prior to September 30, 2026. If granted, a PRV can be redeemed to receive priority review for a different product. Alternatively,
a PRV may be transferred or sold to another sponsor. The FDA also granted Orphan Drug Designation to the Company’s CORDStrom product
on January 6, 2025.

<div align='center'>S-1</div>

Full enrollment in the
Phase II AD trial occurred in late 2024 with 208 patients enrolled.

INKmune for Metastatic Castrate Resistant Prostate Cancer

We believe that INKmune improves
the ability of the patient’s own NK cells to attack their tumor, as INKmune works within the body to activate patients own NK cells
against multiple forms of cancer. INKmune interacts with the patient’s NK cells to convert them from inert resting NK cells into
memory-like NK cells that kill the patient’s cancer cells. INKmune is a replication incompetent proprietary cell line that is given
to the patient after determining that i) the patient has adequate NK cells in their circulation and ii) those NK cells are functional
when exposed to INKmune in vitro. INKmune is designed to be given to patients after their immune system has recovered after cytotoxic
chemotherapy to target the residual disease that remains after treatment with cytotoxic therapy. We believe INKmune can be used to treat
numerous hematologic malignancies and solid tumors including leukemia, multiple myeloma, lymphoma, lung, ovary, breast, renal and prostate
cancer.. The INKmune program is